Bio-Rad Laboratories, Inc.'s (BIO) growth in the upcoming quarters is likely to be backed by its Digital PCR business, which boasts a strong pipeline. The company's Clinical Diagnostics arm is seeing increased demand for quality control, blood typing and diabetes products. Sound financial stability also appears encouraging. However, the impact of macroeconomic challenges on Bio-Rad's operations poses a concern. Persistent reduced demand in the Biopharma segment adds to the worry. Let's delve deeper. Image S ...

Revenues of $610.8 million in the first quarter missed the Zacks Consensus Estimate by 0.2%. The figure dropped 9.8% from the year-ago quarter's levels (down 9.6% at the constant exchange rate or CER). VGM Scores The cumulative net cash flow from operating activities at the end of the first quarter was $697.9 million compared with the year-ago figure of $981.2 million. Bio-Rad belongs to the Zacks Medical - Products industry. Another stock from the same industry, Boston Scientific (BSX) , has gained 4.4% ov ...

About Bio-Techne Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. MINNEAPOLIS, May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the followi ...

AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with more than 18,500 industry leaders from across the globe. About Oncotelic For Oncotelic Therapeutics, Inc.: Investor Relations ir@oncotelic.com Oncot ...

MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2nd-6th in Anaheim, California. The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation in addition to routine icIEF and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) ...

Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel, May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International C ...

PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego. "We are very pleased to participate in this year's Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world," ...

During the conference, Prashant Kohli, Chief Executive Officer of Acasti, will host meetings with pharmaceutical executives to explore partnership and strategic opportunities for the Company's asset portfolio. To connect during the conference, please request a meeting via the BIO International meeting portal or contact mmoyer@lifesciadvisors.com. PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its ...

WALL, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced today that on May 22, 2024, it received a letter (the "Notification Letter") from The Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required per ...

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADP ...